This study checks how the medicine efinopegdutide helps reduce liver fat in people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Liver fat content is the amount of fat in the liver. Efinopegdutide is given either once every two weeks or once a week. The goal is to see which dosing schedule works best over 28 weeks. Safety and how well people can handle the medicine will also be studied.

• The study lasts for 28 weeks.
• Participants must visit the clinic regularly.
• Includes safety checks and tests, like MRI scans.

To join, you need a stable body weight and either no diabetes or controlled Type 2 diabetes. People with other liver diseases or serious health issues can't join. For example, if you have had a heart attack or stroke recently, you won't be able to participate. Also, if you're scared of MRI machines or have metal implants, you can’t have the necessary scans.